Next Article in Journal
Biologically Active Compounds from Goji (Lycium Barbarum L.) Leaves Aqueous Extracts: Purification and Concentration by Membrane Processes
Next Article in Special Issue
Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
Previous Article in Journal
Seminal Plasma Modulates miRNA Expression by Sow Genital Tract Lining Explants
Open AccessFeature PaperReview

Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(6), 934; https://doi.org/10.3390/biom10060934
Received: 31 May 2020 / Revised: 17 June 2020 / Accepted: 18 June 2020 / Published: 20 June 2020
(This article belongs to the Special Issue Immunotoxins: From Design to Clinical Application)
Hepatocellular carcinoma (HCC) accounts for most liver cancers and represents one of the deadliest cancers in the world. Despite the global demand for liver cancer treatments, there remain few options available. The U.S. Food and Drug Administration (FDA) recently approved Lumoxiti, a CD22-targeting immunotoxin, as a treatment for patients with hairy cell leukemia. This approval helps to demonstrate the potential role that immunotoxins can play in the cancer therapeutics pipeline. However, concerns have been raised about the use of immunotoxins, including their high immunogenicity and short half-life, in particular for treating solid tumors such as liver cancer. This review provides an overview of recent efforts to develop a glypican-3 (GPC3) targeting immunotoxin for treating HCC, including strategies to deimmunize immunotoxins by removing B- or T-cell epitopes on the bacterial toxin and to improve the serum half-life of immunotoxins by incorporating an albumin binding domain. View Full-Text
Keywords: recombinant immunotoxin; glypican-3; hepatocellular carcinoma; albumin binding domain; single-domain antibody recombinant immunotoxin; glypican-3; hepatocellular carcinoma; albumin binding domain; single-domain antibody
Show Figures

Graphical abstract

MDPI and ACS Style

Fleming, B.D.; Ho, M. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. Biomolecules 2020, 10, 934.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop